Post-Hoc Live: What’s making biotech IPOs work again?

July 14, 2026 02:31 PM EDT DealsIPOs Post-Hoc Live: What’s mak­ing biotech IPOs work again? Drew Armstrong Executive Editor Late last year, I found my­self talk­ing a lot about what it would take for biotech’s bud­ding ral­ly to be­come a full one. We had deals, good pipeline read­outs and a ris­ing pub­lic stock mar­ket, but one thing was miss­ing — IPOs. Af­ter more than a dozen biotech star­tups have gone pub­lic this year, that piece is locked in. On Wednes­day, Ju­ly 15 at 12 p.m. ET, I’ll be speak­ing with two CEOs who re­cent­ly took their com­pa­nies pub­lic, as well as our own IPO re­porter Kyle LaHu­cik, about what’s dri­ving the steady flow of new of­fer­ings, how it’s dif­fer­ent from the false starts of 2024 and 2025, and how much fur­ther the ral­ly has to run. Join us on YouTube, and you can add us to your Google or Out­look cal­en­dars to get a re­minder when we go live. Para­bilis CEO Math­ai Mam­men and Kail­era CEO Ron Re­naud will give us an in­side look at what it was like to take their com­pa­nies pub­lic. We’ll al­so talk about life as a pub­lic com­pa­ny, and how it’s dif­fer­ent from run­ning a start­up. And I’ll ask Math­ai and Ron about how we’ll know when the run of mar­ket suc­cess might be com­ing to an end — and what they’ll need to do to pre­pare. See you to­mor­row. — Drew Arm­strong, Ex­ec­u­tive Ed­i­tor AUTHOR Drew Armstrong Executive Editor drew@endpointsnews.com @ArmstrongDrew Drew Armstrong on LinkedIn